Show simple item record

dc.contributor.authorNyende, Louis
dc.contributor.authorKalyesubula, Robert
dc.contributor.authorSekasanvu, Emmanuel
dc.contributor.authorByakika-Kibwika, Pauline
dc.date.accessioned2022-01-12T13:27:55Z
dc.date.available2022-01-12T13:27:55Z
dc.date.issued2020
dc.identifier.citationNyende, L., Kalyesubula, R., Sekasanvu, E., & Byakika-Kibwika, P. (2020). Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. BMC nephrology, 21(1), 1-6. https://doi.org/10.1186/s12882-020-01873-yen_US
dc.identifier.urihttps://doi.org/10.1186/s12882-020-01873-y
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1237
dc.description.abstractThere is an increasing burden of non-communicable disease globally. Tenofovir disoproxil fumarate (TDF) is the most commonly prescribed antiretroviral drug globally. Studies show that patients receiving TDF are more prone to renal dysfunction at some point in time during treatment. Evaluation of kidney function is not routinely done in most HIV public clinics. Identification of renal dysfunction is key in resource constrained settings because managing patients with end stage renal disease is costly.en_US
dc.language.isoenen_US
dc.publisherBMC nephrologyen_US
dc.subjectRenal dysfunctionen_US
dc.subjectTenofovir disproxil fumarateen_US
dc.subjectEstimated glomerular filtration rateen_US
dc.titlePrevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional studyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record